Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Inoviq Ltd ( (AU:IIQ) ).
INOVIQ Ltd held its 2025 Annual General Meeting where all resolutions were passed by poll, reflecting strong shareholder support. This outcome is significant for the company’s strategic direction and may positively influence its market positioning in the cancer diagnostics and therapeutics industry.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology, focusing on advancing next-generation diagnostics and therapeutics to transform cancer care. Their product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 177,465
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$47.16M
For an in-depth examination of IIQ stock, go to TipRanks’ Overview page.